Vantage logo

Curevac rides the Covid wave

Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.

Vantage logo

Covid-19 stalls biotech flotations

Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?

Vantage logo

Storm clouds gather for biotech flotations

Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.